Literature DB >> 25438912

Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance).

Melissa C Caughey1, Christy L Avery2, Hanyu Ni3, Scott D Solomon4, Kunihiro Matsushita5, Lisa M Wruck2, Wayne D Rosamond2, Laura R Loehr2.   

Abstract

Anemia is associated with poor prognosis in patients hospitalized with acute decompensated heart failure (ADHF). Whether the impact of anemia differs by heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF) is uncertain. We examined hospital surveillance data captured by the Atherosclerosis Risk in Communities Study from January 1, 2005, to December 31, 2010. Diagnoses of ADHF were validated by standardized physician review of the medical record. Anemia was classified using the World Health Organization criteria (<12 g/dl for women and <13 g/dl for men), and HF type was determined by the ejection fraction (<40% for HFrEF and ≥40% for HFpEF). Hospital length of stay and 1-year mortality outcomes were analyzed by multivariable regression, weighted to account for the sampling design, and adjusted for demographics and clinical covariates. Over 6 years, 15,461 (weighted) hospitalized events for ADHF (59% HFrEF) occurred in the catchment of the Atherosclerosis Risk in Communities, based on 3,309 sampled events. Anemia was associated with a mortality hazard ratio of 2.1 (95% confidence interval [CI] 1.6 to 2.7) in patients classified with HFpEF and 1.4 (95% CI 1.1 to 1.7) in those with HFrEF; p for interaction = 0.05. The mean increase in length of hospital stay associated with anemia was 3.5 days (95% CI 3.4 to 3.6) for patients with HFpEF, compared with 1.8 days (95% CI 1.7 to 1.9) for those with HFrEF; p for interaction <0.0001. In conclusion, the incremental risks of death and lengthened hospital stay associated with anemia are more pronounced in ADHF patients classified with HFpEF than HFrEF.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25438912      PMCID: PMC4694625          DOI: 10.1016/j.amjcard.2014.09.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.

Authors:  Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

2.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

3.  The prevalence, nature, and importance of hematologic abnormalities in heart failure.

Authors:  Colin Berry; John Norrie; Karen Hogg; Michael Brett; Karen Stevenson; John J V McMurray
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

4.  Anemia and heart failure: a community study.

Authors:  Shannon M Dunlay; Susan A Weston; Margaret M Redfield; Jill M Killian; Véronique L Roger
Journal:  Am J Med       Date:  2008-08       Impact factor: 4.965

5.  Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions.

Authors:  Dmitry Abramov; Rose S Cohen; Stuart D Katz; Donna Mancini; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2008-07-31       Impact factor: 2.778

6.  Treatment of anemia with darbepoetin alfa in systolic heart failure.

Authors:  Karl Swedberg; James B Young; Inder S Anand; Sunfa Cheng; Akshay S Desai; Rafael Diaz; Aldo P Maggioni; John J V McMurray; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Yan Sun; Michal Tendera; Dirk J van Veldhuisen
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

7.  Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry).

Authors:  James B Young; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Lilin She; Jie Lena Sun; Clyde W Yancy; Gregg C Fonarow
Journal:  Am J Cardiol       Date:  2008-01-15       Impact factor: 2.778

Review 8.  Anemia and mortality in heart failure patients a systematic review and meta-analysis.

Authors:  Hessel F Groenveld; James L Januzzi; Kevin Damman; Jan van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen; Peter van der Meer
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction.

Authors:  Frank Edelmann; Raoul Stahrenberg; Götz Gelbrich; Kathleen Durstewitz; Christiane E Angermann; Hans-Dirk Düngen; Thomas Scheffold; Christian Zugck; Bernhard Maisch; Vera Regitz-Zagrosek; Gerd Hasenfuss; Burkert M Pieske; Rolf Wachter
Journal:  Clin Res Cardiol       Date:  2011-03-17       Impact factor: 5.460

View more
  8 in total

1.  "Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction.

Authors:  Dawn M Pedrotty; Mariell Jessup
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-02-24

2.  Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure.

Authors:  Margherita Migone de Amicis; David Chivite; Xavier Corbella; Maria Domenica Cappellini; Francesc Formiga
Journal:  Intern Emerg Med       Date:  2017-02-23       Impact factor: 3.397

3.  Performance of Prognostic Risk Scores in Elderly Chinese Patients with Heart Failure.

Authors:  Yalin Cheng; Ke Chai; Wanrong Zhu; Yuhao Wan; Yaodan Liang; Minghui Du; Yingying Li; Ning Sun; Jiefu Yang; Hua Wang
Journal:  Clin Interv Aging       Date:  2021-09-16       Impact factor: 4.458

4.  Association of On-Admission Anemia With 1-Year Mortality in Patients Hospitalized With Acute Heart Failure: Results From the HERO Study.

Authors:  Junlei Li; Chao Jiang; Yiwei Lai; Li Li; Xiaoyan Zhao; Xiaofang Wang; Ling Li; Xin Du; Changsheng Ma; Jianzeng Dong
Journal:  Front Cardiovasc Med       Date:  2022-05-04

5.  Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides.

Authors:  W C Meijers; T Hoekstra; T Jaarsma; D J van Veldhuisen; R A de Boer
Journal:  Neth Heart J       Date:  2016-04       Impact factor: 2.380

6.  Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.

Authors:  Marta Michalska-Kasiczak; Agata Bielecka-Dabrowa; Stephan von Haehling; Stefan D Anker; Jacek Rysz; Maciej Banach
Journal:  Arch Med Sci       Date:  2018-06-11       Impact factor: 3.318

7.  Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction.

Authors:  Clotilde Roy; Alisson Slimani; Christophe de Meester; Mihaela Amzulescu; Agnes Pasquet; David Vancraeynest; Christophe Beauloye; Jean-Louis Vanoverschelde; Bernhard L Gerber; Anne-Catherine Pouleur
Journal:  J Cardiovasc Magn Reson       Date:  2018-08-08       Impact factor: 5.364

8.  Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study.

Authors:  James M Beattie; Rani Khatib; Ceri J Phillips; Simon G Williams
Journal:  Open Heart       Date:  2020-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.